SCHEMBL1637052

SCHEMBL1637052

O=C(c1ccccc1)c1cccc(C#C[Au])c1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PBRM1 Q86U86 1/20 0.42
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 3/20 0.39
S1PR2 O95136 1/20 0.39
HSP90AA1 P07900 1/20 0.39
OPRK1 P41145 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGS1 P23219 2/20 0.38
CXCR1 P25024 2/20 0.38
CXCR2 P25025 2/20 0.38
PTGS2 P35354 2/20 0.38
RECQL P46063 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637166 0.92 SMN1; SMN2 (0.42) ATMTDP1L3MBTL1PBRM1ALDH1A1
SCHEMBL1636978 0.87 ACACB (0.41) TDP1ALDH1A1SMN1; SMN2MAPTS1PR2
SCHEMBL738372 0.86 ALDH1A1 (0.45) ATMTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1636089 0.83 ALDH1A1 (0.48) TDP1L3MBTL1ALDH1A1GLAMAPT
SCHEMBL1637036 0.83 ALDH1A1 (0.36) TDP1ALDH1A1SMN1; SMN2MAPTS1PR2
SCHEMBL1635695 0.82 ALDH1A1 (0.38) ATML3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL1636350 0.82 TTR (0.40) TDP1ALDH1A1SMN1; SMN2MAPTS1PR2
SCHEMBL1636086 0.82 MAPT (0.43) TDP1L3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL1635699 0.80 HPGD (0.48) TDP1L3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL14338517 0.79 ATM (0.65) ATMTDP1L3MBTL1PBRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2042506-B1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES (JP) 2012-12-19 EP disclosed
US-7932398-B2 Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex UBE INDUSTRIES, LTD. (JP) 2011-04-26 US disclosed
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES, LTD. (JP) 2009-09-17 US disclosed
EP-2042506-A1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX Ube Industries, Ltd. (JP) 2009-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX CCRL2, CCNL2, ATXN2L ATM 2810/4885TDP1 4727/4885L3MBTL1 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.